NCT00546286View on ClinicalTrials.gov

A Study to Evaluate the Effectiveness of Cosopt® as First Line Therapy (MK-0507A-153)

PHASE3CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

August 23, 2007

Study Completion Date

August 23, 2007

Conditions
GlaucomaOcular Hypertension
Interventions
DRUG

dorzolamide hydrochloride (+) timolol maleate

"Combination treatment of dorzolamide HCl (2%)/ timolol maleate (0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.~For patients who achieve target IOP at 6 weeks, dorzolamide/timolol is continued for another 6 weeks."

DRUG

Comparator: dorzolamide HCl/timolol maleate + prostaglandin

"Combination treatment of dorzolamide HCl (2%)/timolol maleate(0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.~For patients not achieving target IOP at 6 weeks, a prostaglandin is added for another 6 weeks."

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00546286 - A Study to Evaluate the Effectiveness of Cosopt® as First Line Therapy (MK-0507A-153) | Biotech Hunter | Biotech Hunter